Somerville, MA, United States of America

Bethany Lyn Kormos

This inventor holds 15 USPTO granted patents and 2 published patent applications, plus 5 CIPO patents and 8 EPO patents. Top assignee: Pfizer Corporation. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bethany Lyn Kormos. Retrieved from https://idiyas.com/inventor/bethany-lyn-kormos

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 2)

% Patents Active = 80.0

CIPO Patents = 5 (Patent Applications = 5)

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 8.6

ph-index = 4

Forward Citations = 37(Granted Patents)

Company Filing History:

15 out of 4,488

Pfizer Corporation

patents

Years Active: 2015-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715863 - 5-(thiophen-2-yl)-1 H-tetrazole derivative as BCKDK inhibitors useful for treating various diseases (2026-08-25),

2. 12466803 - BCKDK inhibitors and/or degraders (2025-11-11),

3. 11542270 - BCKDK inhibitors (2023-01-03),

4. 11390623 - 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands (2022-07-19),

5. 11312713 - Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors (2022-04-26),

6. 11161844 - Cyclic substituted imidazo[4,5-c]quinoline derivatives (2021-11-02),

7. 11059833 - BCKDK inhibitors (2021-07-13),

8. 10590128 - 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands (2020-03-17),

9. 10039753 - Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors (2018-08-07),

10. 9695171 - 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors (2017-07-04),

11. 9642855 - Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors (2017-05-09),

12. 9296761 - Triazine derivatives (2016-03-29),

13. 9156845 - 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors (2015-10-13),

14. 9145427 - Triazine derivatives (2015-09-29),

15. 8933224 - Triazine derivatives (2015-01-13),

Title: Innovations and Contributions of Bethany Lyn Kormos

Introduction

Bethany Lyn Kormos is a prominent inventor based in Somerville, MA (US). She has made significant contributions to the field of pharmaceuticals, holding a total of 13 patents. Her work focuses on developing innovative compounds that address various medical conditions.

Latest Patents

Among her latest patents are the BCKDK inhibitors, which describe compounds that serve as inhibitors for branched-chain alpha keto acid dehydrogenase kinase. These compounds are particularly useful in treating conditions such as diabetes, NASH, and heart failure. Another notable patent involves 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands. This invention provides compounds that are beneficial for treating D3-mediated disorders, including substance addiction, schizophrenia, cognitive impairment, Parkinson's disease, and depression.

Career Highlights

Bethany is currently employed at Pfizer Corporation, where she continues to innovate and develop new pharmaceutical solutions. Her extensive research and development efforts have positioned her as a key player in her field.

Collaborations

Throughout her career, Bethany has collaborated with notable colleagues, including Patrick Robert Verhoest and Jaclyn Louise Henderson. These partnerships have further enhanced her research and contributed to her success in the industry.

Conclusion

Bethany Lyn Kormos exemplifies the spirit of innovation in the pharmaceutical industry. Her contributions through her patents and collaborations have the potential to significantly impact the treatment of various medical conditions.

Profile summary based on public USPTO records.